ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering

SKILLMAN, New Jersey, December 6, 2010 - ConvaTec Healthcare, a world-leading developer, manufacturer and marketer
of innovative medical technologies for community and hospital care, today
announced that in connection with a refinancing of its debt under its
existing senior secured and mezzanine facilities and in combination with new
senior secured credit facilities, it is offering $1,870,000,000 (equivalent)
in Senior Secured Notes and Senior Notes. The offering of the new notes will
not be registered under the Securities Act or any state securities laws and
the new notes may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act of 1933, as amended and applicable state securities laws.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical
technologies. With four key focus areas - Ostomy Care, Wound Therapeutics,
Continence and Critical Care, and Infusion Devices - ConvaTec products
support healthcare professionals from the hospital to the community health
setting. From its operational headquarters in Skillman, New Jersey, the
company conducts business in over 100 countries, serving consumers and their
health care professionals on six continents. For more information, please
visit www.convatec.com.

Certain statements in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward looking statements are all statements other than statements of
historical facts. Certain of these forward looking statements are identified
by terminology such as "aim," "anticipate," "believe," "continue," "could,"
"estimate," "expect," "forecast," "guidance," "intend," "may," "plan,"
"potential," "predict," "projected," "should," or "will" or the negative of
such terms or other comparable terminology. Others can be identified from the
context in which the statements are made. These statements involve a number
of risks and uncertainties. Any forward-looking statements that we make
herein and in future reports and statements are not guarantees of future
performance, and actual results may differ materially from those in such
forward-looking statements as a result of various factors relating to our
strategy, outlook and growth prospects, including our operational and
financial targets; the expected growth of the markets in which we operate;
the competitive environment in which we operate; the economic outlook in
general and, in particular, economic conditions in the European and U.S.
markets; growth in demand for our products, increases in the penetration of
our products into their respective markets, reimbursement rates for our
products, or similar measures; and our expansion plans, including planned
expansion into and growth in emerging markets; our ability to gain necessary
regulatory approvals and desirable reimbursement rates for our newly
developed products and technologies; and our ability to market and launch
attractive new product designs and technologies. All forward-looking
statements made in this press release are made as of the date hereof, and the
risk that actual results will differ materially from expectations expressed
herein will increase with the passage of time. The Company undertakes no duty
to publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.

This announcement is being distributed to and is directed only at (i)
persons who are outside the United Kingdom or (ii) persons who have
professional experience in matters relating to investments falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and
other persons to whom it may lawfully be communicated, falling within Article
49(2) (a) to (d) of the Order (all such persons together being referred to as
"relevant persons"). Any investment activity to which this communication
relates will only be available to and will only be engaged with, relevant
persons. Any person who is not a relevant person should not act or rely on
this document or any of its contents.

In connection with the issuance of notes, the stabilizing manager may
over-allot the notes or effect transactions with a view to supporting the
market price of the notes, in each case at a level higher than that which
might otherwise prevail. However, there is no assurance that such stabilizing
manager (or persons acting on behalf of such stabilizing manager) will
undertake such stabilization actions. Any stabilization action may begin on
or after the date on which adequate public disclosure of the final terms of
the offer of the notes is made and, if begun, may be ended at any time, but
must end no later than the earlier of 30 calendar days after the issue date
of the notes and 60 calendar days after the date of the allotment of the
notes.

This document is an advertisement for purposes of applicable measures
implementing Directive 2003/71/EC.

This announcement is not an offer to sell or the solicitation of an offer
to buy the new notes in any jurisdiction in which such an offer, solicitation
or sale would be unlawful.

    Media Contact

    Nimisha Savani
    +1-908-904-2522
    Nimisha.savani@convatec.com

Nimisha Savani, ConvaTec Healthcare, +1-908-904-2522, Nimisha.savani at convatec.com